5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
MiNK Therapeutics, Inc. (NASDAQ:INKT) announced Monday the publication of a case report in the journal Oncogene describing a patient with metastatic, treatment-refractory testicular cancer who achieved complete and durable remission following treatment with the company’s allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797. According to the SEC filing, the patient had previously received multiple lines of therapy, including platinum-based chemotherapy, autologous stem cell transplant, and various immune checkpoint inhibitors, before a single infusion of agenT-797 in combination with nivolumab.
The report states that the patient experienced a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years after treatment. Donor iNKT cells were detectable for up to six months following infusion, and the treatment was reported to be well tolerated, with no cytokine release syndrome or graft-versus-host disease observed.
In addition, at the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in second-line gastric cancer. The company reported evidence of immune activation, increased tumor infiltration, and early signals of tumor control in patients who had previously not responded to checkpoint inhibitors. The filing notes that extended survival beyond 12 months was observed in several patients.
A separate case report published in Oncogene described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival after a single infusion of agenT-797 with nivolumab.
The company stated that its ongoing Phase 2 trial in gastric cancer (NCT06251973) is actively enrolling, with additional data readouts expected in the coming months. InvestingPro analysis reveals that while the company currently operates with moderate debt levels, analysts have recently revised their earnings expectations downward for the upcoming period. With the next earnings report due on August 14, 2025, investors seeking deeper insights can access the comprehensive Pro Research Report, which provides detailed analysis of INKT’s financial health and growth prospects.
This information is based on a statement provided in a press release and detailed in the company’s recent SEC filing.
In other recent news, MiNK Therapeutics has reported a complete remission in a patient with metastatic testicular cancer following treatment with its iNKT cell therapy, agenT-797. This breakthrough was detailed in a publication in Nature’s Oncogene, highlighting the patient’s remission after a single infusion of agenT-797 alongside nivolumab. The patient had previously failed multiple treatments, including chemotherapy and stem cell transplant, and remains disease-free more than two years later. H.C. Wainwright has maintained a Buy rating on MiNK Therapeutics, setting a price target of $35.00, following these promising results. The company continues to enroll patients in its ongoing Phase 2 trial for gastric cancer, with survival beyond 12 months observed in several cases. Additionally, MiNK Therapeutics has received a grant from the National Institutes of Health to further develop its allo-iNKT cell therapy platform for preventing graft-versus-host disease. This grant supports collaboration with the University of Wisconsin, focusing on leveraging transplant immunology expertise. MiNK Therapeutics is also advancing other immune technologies, including T cell receptor-based therapies, to provide durable treatments for various conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.